Venture&Growth
Location
San Jose (CA), USA
Since: 2019
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
US-based MedTech focused on treatment of hypertension via renal denervation.
Ablative Solutions is a medical device company that has developed a best-in-class drug delivery catheter, the Peregrine SystemTM, which delivers a neurolytic agent to the adventitia of the renal arteries for the purposes of ablating the surrounding nerves.
This procedure, known as renal denervation, has a potentially significant effect in the treatment of hypertension.
The Ablative Solutions procedure is quick, relatively painless and results in deep, circumferential ablation of the renal nerves.
The company has CE Mark and is currently engaged in clinical studies in Europe and the United States.
More Ablative Solutions news
Gilde Healthcare’s Ablative Solutions, Inc. meets Primary Endpoint in Pivotal Trial for Hypertension
Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions
Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension
Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer
Venture&Growth
SpliceBio
SpliceBio is a Spanish therapeutics company addressing the key limitations of current gene therapy. It harnesses its proprietary Protein Splicing platform to develop next-generation gene therapies, based on engineered inteins pioneered at the Muir Lab at Princeton University. The company
Venture&Growth
Withings
French Healthtech company commercializing personal health devices.
Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).
